大唾液腺癌肉瘤的治疗模式与结局
基于美国国家癌症数据库(NCDB)2004—2018年154例大唾液腺癌肉瘤患者的历史队列研究显示,多数为腮腺、高级别、局部晚期肿瘤,手术联合辅助放疗最常见;中位随访36个月,3年总生存率57.6%(95%CI 48.7%-68.0%)。多因素分析中年龄(HR 1.02;95%CI 1.01-1.04;P=.03)和pT分期(HR 2.51;95%CI 1.27-4.95;P=.008)与生存显著相关。
要点
- 大唾液腺癌肉瘤罕见,多发生于腮腺(122/154,79%),多数为高级别(93/95,95%)。
- 手术联合辅助放疗最常见(75/154,49%),3年总生存率57.6%(95%CI 48.7%-68.0%)。
核心结论
- 癌肉瘤是罕见的唾液腺肿瘤,常以局部晚期阶段就诊,即便采用多模式治疗,结局仍较差。
- 在缺乏临床试验数据的情况下,NCDB的这些数据或可指导临床医生管理这一罕见疾病。
研究设计与样本
- 历史队列研究,数据来自美国国家癌症数据库(NCDB)。
- 纳入2004年至2018年间诊断的大唾液腺癌肉瘤患者,共154例。
- 分析患者人口学特征、肿瘤特征、治疗与生存,并对接受手术的患者进行Cox回归分析。
主要发现
- 诊断时中位年龄66岁(四分位距55-76岁),男性92例(60%)。
- 肿瘤位于腮腺122例(79%),下颌下腺21例(14%)。
- 高级别肿瘤93例(95%),局部晚期(pT3-4)65例(62%),淋巴结阳性35例(36%)。
- 最常见治疗为手术联合辅助放疗75例(49%)。
- 中位随访36个月,3年总生存率57.6%(95%CI 48.7%-68.0%)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为,在缺乏临床试验数据的情况下,NCDB数据或可指导临床医生管理这一罕见疾病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Carcinosarcoma of the salivary gland is a rare malignant biphasic tumor. The present study investigates the epidemiology and clinical behavior of carcinosarcoma of the major salivary glands using the National Cancer Database (NCDB). STUDY DESIGN: Historical cohort study. SETTING: NCDB. METHODS: All tumors were selected between 2004 and 2018. Patient demographics, tumor characteristics, treatments, and survival were analyzed. Cox regression analysis was performed in surgically treated patients. RESULTS: We identified 154 patients in the NCDB with carcinosarcoma of the salivary gland. Median age at diagnosis was 66 years (interquartile range, 55-76). Most patients were male (n = 92, 60%). The majority of tumors were in the parotid (n = 122, 79%), followed by submandibular gland (n = 21, 14%). The majority were high grade (n = 93, 95%), and a significant portion had locally advanced disease (pT3-4; n = 65, 62%). Nodal disease was present in more than one-third (n = 35, 36%). The most common treatment was surgery with adjuvant radiotherapy (n = 75, 49%). With a median follow-up of 36 months, the 3-year overall survival was 57.6% (95% CI, 48.7%-68.0%). In univariable analysis, advanced pT stage, pN+ disease, and positive margins were associated with worse survival. In multivariable analysis, age (hazard ratio, 1.02; 95% CI, 1.01-1.04; P = .03) and pT stage (hazard ratio, 2.51; 95% CI, 1.27-4.95; P = .008) remained significant. CONCLUSION: Carcinosarcoma is a rare salivary gland tumor that frequently presents at a locally advanced stage. Despite multimodality treatments, the outcomes are poor. In the absence of clinical trial data, these data from the NCDB could guide clinicians in the management of this rare disease.
引用
- Talwar A, Patel E, Tam M, et al. Patterns of Care and Outcomes of Carcinosarcoma of the Major Salivary Glands. Otolaryngol Head Neck Surg. 2023. PMID: 35998038. doi:10.1177/01945998221120646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。